Inside Precision Medicine July 23, 2024
IPM Staff

Cardurion Pharmaceuticals has raised a $260M Series B financing led by Ascenta Capital to support development of a first-in-class phosphodiesterase-9 (PDE9) inhibitor for heart failure and a Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor with “broad therapeutic potential,” according to the company. Both drug candidates are in Phase II trials. The cardiovascular drug market is one of the world’s largest.

The biotech is working on signaling pathways that regulate heart cell function with the goal of reversing pathophysiological mechanisms that drive cardiovascular disease.The company’s two lead drug candidates are PDE9 inhibitor CRD‑750 and CaMKII inhibitor CRD-4730. The funds will also be used to expand the cardiovascular indications for Cardurion’s portfolio of drug candidates and acquire new drug candidates.

PDE9 is elevated...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Coalition encourages employers to offer obesity coverage
Bringing Systems Thinking To Drug Value Assessment
How Can Startups Navigate the Difficult Funding Environment
As medication prices rise, hospitals turn to drugmakers

Share This Article